Skin Cancer & Surgery

Beauty Editor's Nose Spot Turned Out to Be Morpheaform BCC

Skin Cancer Warrior Warns: Your Skin Never Forgets
voltamax / pixabay

A small red spot on the center of her nose that Sara Eggenberger covered with concealer for roughly six months turned out to be morpheaform basal cell carcinoma — a rare, aggressive BCC subtype whose tentacle-like extensions had spread beneath her skin, up her nose and toward her eye.

Eggenberger, an editor at NewBeauty and an on-air television correspondent, is now sharing her diagnosis story publicly to raise awareness and funds for The Skin Cancer Foundation. Her case carries a lesson dermatologists repeat constantly but patients often ignore: a spot that never goes away is a spot that needs a professional look.

How the diagnosis unfolded

Eggenberger first noticed the spot as what she assumed was "a mark of aging." It didn't hurt and didn't demand attention. As someone in makeup constantly for on-camera work, covering it felt completely normal. In hindsight, she writes, "if there's a spot you keep covering because it never goes away, that's worth paying attention to."

The turning point came about six months later, during a routine facial. Her aesthetician compared her skin to photos from a previous visit and flagged that the spot had significantly grown. A couple of weeks after that, her dermatologist biopsied it. One week later came the call: basal cell carcinoma.

She remembers exactly where she was — late afternoon, preparing to host a Fourth of July party. Her first instinct was to compartmentalize and deal with it after the weekend. Then, she writes, came "a gut punch" — disbelief that someone who wears sunscreen daily and never lies out in the sun could get skin cancer.

That disbelief, she now argues, is misplaced. "Your skin never forgets," she writes. "Every burn, every tanning bed session, every summer spent chasing a glow from childhood on — it all leaves an imprint."

A rare, aggressive subtype

The clinical details matter here. Morpheaform BCC makes up only a small percentage of basal cell cases. During surgery, Eggenberger's surgeons found subclinical extension spreading under the visible surface — what appeared on the skin was "only a small part of what was happening underneath," a hallmark of the subtype and the reason margin control matters so much in treatment.

Because the cancer sat in the center of her nose, and because her face is central to her professional life, she feared the scar. Her surgeon, she says, understood both priorities: remove the cancer completely, but don't let the scar define her. "Skin cancer is something that happened to me. I didn't want to be reminded of it every time I looked in the mirror."

The cancer was caught early and was treatable — a fact she says left her feeling grateful alongside the fear.

What does this change for patients?

Eggenberger's core message is early detection. She wasn't consistent about regular skin checks before her diagnosis, believing that working around skin experts gave her a "false sense" of staying on top of her skin health. Anything new, changing or unusual on the skin deserves attention, she writes — the skin signals when something isn't right.

She also flags a generational concern for parents: her teen and tween are now seeing "tanmaxxing" content on social media, where a high UV index number gets framed as "a good time to tan." She grew up when sunscreen was pool-only and a sunburn meant "a great day outside." That cultural shift is why she calls The Skin Cancer Foundation's education work vital — the organization, she says, sets the standard for educating both the public and the medical community on prevention, early detection and treatment.

Her closing argument, aimed at readers: skin cancer is preventable, treatable and too important to ignore — and a trusted resource like SkinCancer.org can counter the misinformation that fills search results after a diagnosis.

Source: skincancer.org

Share this article:

Olivia Hart

Show full bio

News editor covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Olivia Hart →

Related articles

« Previous article